Randomized Controlled Trial Comparing Oral Doxifluridine Plus Oral Cyclophosphamide With Doxifluridine Alone in Women With Node-Positive Breast Cancer After Primary Surgery
Takeshi Tominaga(Tokyo Metropolitan Komagome Hospital), Osahiko Abe(Keio University), Tadashi Ikeda(Keio University), Izo Kimijima(Hokkaido University Hospital), Yasuo Ohashi(Chuo University), Masakazu Toi(Mukogawa Women's University), Koichi Hirata(Japan Coal Energy Center), Shigeto Miura(Tohoku University), Susumu Yamaguchi(Hokkaido University Hospital), Hiroki Koyama(Osaka Medical Center for Cancer and Cardiovascular Diseases), Yasumasa Monden(Hokkaido University Hospital), Jun Ota(Hokkaido University Hospital), Tadaoki Morimoto(Hokkaido University Hospital), Yasuo Nomura(Hokkaido University Hospital), Shinzaburo Noguchi(Hyogo Prefectural Nishinomiya Hospital), Keizō Sugimachi(Kyushu University), Kazuaki Asaishi(Hokkaido University Hospital), Tetsuya Toge(Hiroshima University), Hiroshi Sonoo(Okayama Prefecture)
Cited by 18
Related Papers
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
|Journal of Clinical Oncology|2017|1.7k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
|JAMA Oncology|2019|1k
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830